RTI (Regeneration Technologies) restructures as it seeks to return to profitability
This article was originally published in Clinica
Regeneration Technologies (RTI) has announced restructuring measures, including the loss of some 52 jobs, at the same time as releasing first-quarter results with an 11% drop in revenues. The steps will include "significant cost cutting measures", and will allow the company to focus on its key spinal and orthopaedic allografts. In addition, the company's founder, Jamie Grooms, is resigning from the board, but will continue in a consulting capacity on emerging technologies.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.